JP Morgan has recently reduced Organon & Co (OGN) stock to Underweight rating, as announced on September 6, 2024, according to Finviz. Earlier, on November 3, 2023, Goldman had reduced the stock from ...

Despite announcing strong earnings, Organon & Co.'s ( NYSE:OGN ) stock was sluggish. We did some digging and found ...

Organon Philippines, a women’s health company, recently unveiled its Her Health Finder, an online tool that aims to empower ...

On October 30, 2024, Shanghai Henlius Biotech and Organon announced that the FDA has accepted the Biologic License Application (BLA) for HLX14, a proposed biosimilar to PROLIA/XGEVA (denosumab). In ...

Organon's OGN short percent of float has risen 28.4% since its last report. The company recently reported that it has 12.53 ...

They made the remarks as the international exchange platform, in its seventh edition this year, has attracted many leading ...

International Assets Investment Management LLC increased its holdings in Organon & Co. (NYSE:OGN – Free Report) by 1,851.8% in the third quarter, HoldingsChannel.com reports. The institutional ...

On Tuesday, Organon & Co (OGN) stock saw a decline, ending the day at $16.46 which represents a decrease of $-0.46 or -2.72% from the prior close of $16.92. The stock opened at $16.74 and touched a ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a ...

The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

THE Quezon City Government announced through a statement that it awarded a total of P6 million in equity-free grants to six local technology startups under the “Startup QC” program to support and ...

Organon (OGN) announced that the FDA extended by three months the target action date of its review of the supplemental New Drug Application, or ...